Shares of Senores Prescription drugs Ltd surged 6% to hit the day’s excessive of Rs 565 on twenty first February after its subsidiary signed an settlement to amass the Abbreviated New Drug Software (ANDA) for Roflumilast 250 mcg and 500 mcg tablets.
Roflumilast is used to scale back the chance of Persistent Obstructive Pulmonary Illness (COPD) exacerbations in sufferers with extreme COPD linked to continual bronchitis and a historical past of flare-ups.
The market measurement of Roflumilast within the US stood at $32 million as of MAT June 2024 and grew to $46 million by MAT September 2024, in accordance with the submitting.
Swapnil Shah, Managing Director of Senores Prescription drugs, said that buying Roflumilast Pill ANDA is a strategic transfer to strengthen their speciality distribution portfolio.
Roflumilast’s manufacturing will happen domestically at Senores’ US web site, making certain higher management over manufacturing and distribution.
This acquisition additionally marks the corporate’s entry into the continual bronchitis remedy area, increasing its attain in respiratory care.
The transfer aligns with Senores’ technique of figuring out area of interest, under-penetrated generic formulations to handle unmet healthcare wants.
At 12:43 PM, the shares of Senores Pharma have been buying and selling 4.19% increased at Rs 556.15 on NSE.
Keep Forward with Senores Pharma. Ask the Analyst.
Unlock worthwhile alternatives daily! Unicorn Indicators supplies actionable intraday buying and selling alerts for shares and futures. Don’t miss out – obtain Unicorn Indicators and begin profitable now!
